Cord blood nesfatin-1 and apelin-36 levels in gestational diabetes mellitus

Abstract

To assess maternal serum and cord blood apelin-36 and nesfatin-1 concentrations in pregnant women with and without gestational diabetes mellitus (GDM). Thirty pregnant women with GDM and 30 gestational age matched healthy pregnant subjects participated to the study. Maternal serum and cord blood nesfatin-1 and apelin-36 levels were measured with ELISA, at the time of birth. The relationships between maternal serum and cord blood nesfatin-1 and apelin-36 levels, anthropometric and metabolic parameters were also assessed. Maternal serum apelin-36 levels were found higher (13.5 ± 8.3 vs. 9.6 ± 5.9 ng/ml, P = 0.001) and nesfatin-1 levels were found lower (5.5 ± 8.1 vs. 8.1 ± 23.9 ng/ml, P = 0.001) in patients with GDM compared with control pregnant women. However, the cord blood apelin-36 levels (8.8 ± 4.3 and 8.2 ± 1.9 ng/ml, P = 0.618) and nesfatin-1 levels (5.4 ± 4.0 and 6.2 ± 10.3 ng/ml, P = 0.688) were similar in the GDM and control groups, respectively. Maternal serum apelin-36 and nesfatin-1 levels correlated positively with their respective cord blood levels. Maternal serum and cord blood apelin-36 levels correlated negatively with the gestational age and birth weight. Similarly maternal serum and cord blood nesfatin-1 levels correlated negatively with the gestational age, but there was no correlation with the birth weight. We did not find a correlation between maternal serum apelin-36 and nesfatin-1 levels, maternal age, BMI, fasting glucose, fasting insulin, and HOMA-IR. Also cord blood apelin-36 and nesfatin-1 levels did not correlate with the maternal age, BMI, HOMA-IR, cord blood glucose, and cord blood insulin levels. Our results indicate that apelin-36 concentrations increase and nesfatin-1 concentrations decrease in maternal serum of women with GDM.

The effects of short-term high-intensity interval training vs. moderate-intensity continuous training on plasma levels of nesfatin-1 and inflammatory markers

“…In literature, several studies have examined the correlation between nesfatin and these parameters, and the results are controversial. In line with our results, previous studies have shown a positive correlation [2,38] , others have shown a negative correlation [10,11] , and some reports found no significant correlation at all [39] . The differences of study designs, experimental conditions, ethnicity, participant selection (gender, body mass range, age, eating pattern, and physical fitness level), and different assessment methods (ELISA recognizing NUCB2 and nesfatin-1 vs. recognizing only nesfatin-1) may explain these differences.…”

Serum nesfatin-1 levels are decreased in pregnant women newly diagnosed with gestational diabetes

“…In the present study, we did not find any correlation between nesfatin-1 and fasting glucose, 1-h glucose after 50-g glucose screening test, 1-h, 2-h, and 3-h glucose after 100-g oral glucose tolerance test, HbA1c, HOMA-IR, and BMI. We found a significant positive correlation between nesfatin-1 and gestational age, contrary to the results of the study by Aslan and cols., as they had observed a negative correlation between nesfatin-1 and gestational age (11).…”

“…In this study, Aslan and cols. assessed both serum and cord blood apelin and nesfatin-1 levels in pregnant women with GDM and in healthy pregnant women (11). Cord blood nesfatin-1 and apelin-36 levels were comparable between women with GDM and controls, serum apelin-36 concentrations were found to be higher, and serum nesfatin-1 concentrations were found to be lower in women with GDM compared to controls.…”

Sex-specific regulation of NUCB2/nesfatin-1: Differential implication in anxiety in obese men and women

“…One has to keep in mind that the comparison of NUCB2/nesfatin-1 levels between studies is often difficult as discussed before (Hofmann et al, 2013). Concentrations of circulating NUCB2/nesfatin-1 considered as "normal" were reported in a wide range between 0.2 and 8 ng/ml (Aydin et al, 2009;Aslan et al, 2012). In the present study NUCB2/nesfatin-1 plasma levels were lower than those of a previous report (Ari et al, 2011) (∼0.35 ng/ml vs. ∼3 ng/ml), which is surprising because higher levels would have been expected due to a higher grade of overweight/obesity in the present study (mean BMI 49 kg/m 2 vs. 24 kg/m 2 ).…”